Compare VENUS REMEDIES with J.B.Chemicals - Equitymaster

Helping You Build Wealth With Honest Research
Since 1996. Try Now

  • MyStocks

MEMBER'S LOGINX

     
Login Failure
   
     
   
     
 
 
 
(Please do not use this option on a public machine)
 
     
 
 
 
  Sign Up | Forgot Password?  

VENUS REMEDIES vs J.B.CHEMICALS - Comparison Results

J.B.CHEMICALS 
   Change

JB Chemicals and Pharmaceuticals Limited (JBCPL), the flagship of the Unique Group, is one of the India's leading transnational pharmaceutical company. The company has 11 manufacturing facilities at four locations in India (Belapur, Ankleshwar, Panol... More

DO YOU LIKE THESE REPORTS? TELL US!

Current Valuations

    VENUS REMEDIES J.B.CHEMICALS VENUS REMEDIES/
J.B.CHEMICALS
 
P/E (TTM) x -1.5 15.6 - View Chart
P/BV x 0.1 2.1 5.0% View Chart
Dividend Yield % 0.0 0.5 -  

Financials

 VENUS REMEDIES   J.B.CHEMICALS
EQUITY SHARE DATA
    VENUS REMEDIES
Mar-18
J.B.CHEMICALS
Mar-18
VENUS REMEDIES/
J.B.CHEMICALS
5-Yr Chart
Click to enlarge
High Rs126363 34.7%   
Low Rs61255 24.0%   
Sales per share (Unadj.) Rs301.8169.1 178.4%  
Earnings per share (Unadj.) Rs-24.916.6 -149.8%  
Cash flow per share (Unadj.) Rs2.523.4 10.9%  
Dividends per share (Unadj.) Rs02.00 0.0%  
Dividend yield (eoy) %00.6 0.0%  
Book value per share (Unadj.) Rs293.3172.5 170.0%  
Shares outstanding (eoy) m12.3483.57 14.8%   
Bonus/Rights/Conversions -BB-  
Price / Sales ratio x0.31.8 17.0%   
Avg P/E ratio x-3.818.6 -20.2%  
P/CF ratio (eoy) x36.713.2 278.4%  
Price / Book Value ratio x0.31.8 17.8%  
Dividend payout %012.0 0.0%   
Avg Mkt Cap Rs m1,15425,827 4.5%   
No. of employees `0000.93.8 24.5%   
Total wages/salary Rs m3932,511 15.7%   
Avg. sales/employee Rs Th4,026.13,747.4 107.4%   
Avg. wages/employee Rs Th425.0665.7 63.8%   
Avg. net profit/employee Rs Th-331.8367.8 -90.2%   
INCOME DATA
Net Sales Rs m3,72414,135 26.3%  
Other income Rs m23366 6.2%   
Total revenues Rs m3,74714,501 25.8%   
Gross profit Rs m3952,178 18.1%  
Depreciation Rs m338570 59.4%   
Interest Rs m35435 1,015.2%   
Profit before tax Rs m-2751,940 -14.2%   
Minority Interest Rs m00-   
Prior Period Items Rs m00-   
Extraordinary Inc (Exp) Rs m00-   
Tax Rs m32552 5.7%   
Profit after tax Rs m-3071,387 -22.1%  
Gross profit margin %10.615.4 68.8%  
Effective tax rate %-11.528.5 -40.3%   
Net profit margin %-8.29.8 -84.0%  
BALANCE SHEET DATA
Current assets Rs m2,63810,470 25.2%   
Current liabilities Rs m2,3052,749 83.8%   
Net working cap to sales %8.954.6 16.4%  
Current ratio x1.13.8 30.1%  
Inventory Days Days13555 245.4%  
Debtors Days Days4678 59.7%  
Net fixed assets Rs m4,8715,811 83.8%   
Share capital Rs m123167 73.8%   
"Free" reserves Rs m3,49614,248 24.5%   
Net worth Rs m3,61914,416 25.1%   
Long term debt Rs m1,3740-   
Total assets Rs m7,50917,649 42.5%  
Interest coverage x0.256.6 0.4%   
Debt to equity ratio x0.40-  
Sales to assets ratio x0.50.8 61.9%   
Return on assets %0.68.1 7.8%  
Return on equity %-8.59.6 -88.1%  
Return on capital %1.613.7 11.6%  
Exports to sales %00-   
Imports to sales %13.90-   
Exports (fob) Rs mNANA-   
Imports (cif) Rs m517NA-   
Fx inflow Rs m06,164 0.0%   
Fx outflow Rs m5171,334 38.7%   
Net fx Rs m-5174,829 -10.7%   
CASH FLOW
From Operations Rs m5141,231 41.8%  
From Investments Rs m-123-208 59.2%  
From Financial Activity Rs m-387-595 65.0%  
Net Cashflow Rs m4427 1.0%  

Share Holding

Indian Promoters % 32.9 55.4 59.3%  
Foreign collaborators % 0.0 0.3 -  
Indian inst/Mut Fund % 0.2 3.4 5.3%  
FIIs % 0.6 3.9 14.9%  
ADR/GDR % 0.0 0.0 -  
Free float % 66.4 37.0 179.5%  
Shareholders   20,121 30,437 66.1%  
Pledged promoter(s) holding % 36.4 0.0 -  
NM: Not Meaningful
Source: Company Annual Reports, Regulatory Filings, Equitymaster

Compare VENUS REMEDIES With:   SHASUN PHARMA  WYETH LTD  GSK PHARMA  FULFORD INDIA  DR. REDDYS LAB  

Compare VENUS REMEDIES With:   MYLAN (US)  ACTAVIS (US)  ADCOCK INGRAM (S. Africa)  TEVA PHARMA (Israel)  



Today's Market

Indian Stock Markets Remain in Green This Week: Is the Rebound Here?(Podcast)

After a long period of underperformance, stock markets traded in green territory throughout the week. So, is this is a trend reversal and is the bottom forming in the market?

Related Views on News

VENUS REMEDIES Announces Quarterly Results (4QFY19); Net Profit Down 11.1% (Quarterly Result Update)

Jun 12, 2019 | Updated on Jun 12, 2019

For the quarter ended March 2019, VENUS REMEDIES has posted a net profit of Rs 104 m (down 11.1% YoY). Sales on the other hand came in at Rs 864 m (down 7.3% YoY). Read on for a complete analysis of VENUS REMEDIES's quarterly results.

J.B.CHEMICALS Announces Quarterly Results (4QFY19); Net Profit Up 91.2% (Quarterly Result Update)

May 24, 2019 | Updated on May 24, 2019

For the quarter ended March 2019, J.B.CHEMICALS has posted a net profit of Rs 422 m (up 91.2% YoY). Sales on the other hand came in at Rs 4 bn (up 18.9% YoY). Read on for a complete analysis of J.B.CHEMICALS's quarterly results.

J.B.CHEMICALS 2017-18 Annual Report Analysis (Annual Result Update)

Mar 28, 2019 | Updated on Mar 28, 2019

Here's an analysis of the annual report of J.B.CHEMICALS for 2017-18. It includes a full income statement, balance sheet and cash flow analysis of J.B.CHEMICALS. Also includes updates on the valuation of J.B.CHEMICALS.

VENUS REMEDIES Announces Quarterly Results (3QFY19); Net Profit Down 2301.8% (Quarterly Result Update)

Feb 22, 2019 | Updated on Feb 22, 2019

For the quarter ended December 2018, VENUS REMEDIES has posted a net profit of Rs 119 m (down 2301.8% YoY). Sales on the other hand came in at Rs 691 m (down 25.8% YoY). Read on for a complete analysis of VENUS REMEDIES's quarterly results.

VENUS REMEDIES 2017-18 Annual Report Analysis (Annual Result Update)

Dec 21, 2018 | Updated on Dec 21, 2018

Here's an analysis of the annual report of VENUS REMEDIES for 2017-18. It includes a full income statement, balance sheet and cash flow analysis of VENUS REMEDIES. Also includes updates on the valuation of VENUS REMEDIES.

More Views on News

Most Popular

My 3 Best Small-cap Stocks to Get Rich in this Market Rebound(Profit Hunter)

Oct 14, 2019

This is once in a decade opportunity to make a killing from smallcap rebound.

Finally, Is the Share Price of Yes Bank Ready for a Rebound?(The 5 Minute Wrapup)

Oct 7, 2019

Here's what every individual investor must know about Yes Bank...

Two Stocks to Buy in the Great Indian Festival(Profit Hunter)

Oct 11, 2019

Discounts are not just limited to E-tailers. You can buy stocks at 50% off too. Here are two stocks to buy now.

The One Stock I Like in this Market(The 5 Minute Wrapup)

Oct 10, 2019

There are rare periods in markets when you get good quality stocks at attractive valuations. Is this one such period?

5 Smart Money Stocks to Profit from the Market Rebound(The 5 Minute Wrapup)

Oct 11, 2019

Now is the time to put money in these 5 stocks to take advantage of the recovery in the economy and the markets.

More

Get the Indian Stock Market's
Most Profitable Ideas

How To Beat Sensex Guide 2020
Get our special report, How to Beat Sensex Nearly 3X Now!
We will never sell or rent your email id.
Please read our Terms

VENUS REMEDIES SHARE PRICE


Oct 18, 2019 (Close)

TRACK VENUS REMEDIES

  • Track your investment in VENUS REMEDIES with Equitymaster's Portfolio Tracker. Set live price alerts, get research alerts and more. Get access now...
  • Add To MyStocks

MORE ON VENUS REMEDIES

VENUS REMEDIES 8-QTR ANALYSIS

COMPARE VENUS REMEDIES WITH

MARKET STATS